Carcinoma  >>  oxaliplatin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

30 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00061815: Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Completed
3
102
US
cetuximab, Erbitux™, oxaliplatin, Eloxatin®, leucovorin, Wellcovorin®, 5-fluorouracil, 5-FU
Eli Lilly and Company, Bristol-Myers Squibb
Colorectal Cancer
12/04
11/05
NSABP-C-07, NCT00004931: Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

Completed
3
2472
US
leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, laboratory biomarker analysis
National Cancer Institute (NCI)
Stage II Colon Cancer, Stage III Colon Cancer
09/05
 
NCT00058149: Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed
3
US, RoW
gemcitabine hydrochloride, oxaliplatin
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Pancreatic Cancer
07/06
 
SWOG-N9841, NCT00005036: Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Completed
3
560
US
irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, quality-of-life assessment, quality of life assessment
National Cancer Institute (NCI), Southwest Oncology Group, Eastern Cooperative Oncology Group
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
12/06
 
NCT00077233: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Terminated
3
238
US
cetuximab, C225, 5-FU, 5-fluorouracil, irinotecan, CPT-11, leucovorin, calcium folinate, oxaliplatin, Eloxatin
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Bristol-Myers Squibb, Eli Lilly and Company
Colorectal Cancer
12/06
06/10
NCT00056446: Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Checkmark P3 data (CRC) - CONFIRM-1
Aug 2012 - Aug 2012: P3 data (CRC) - CONFIRM-1
Completed
3
855
US, Canada, Europe, RoW
Vatalanib, PTK787/ZK 222584
Novartis Pharmaceuticals, Bayer
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
01/07
01/07
NCT00070122: Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

Terminated
3
2200
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, capecitabine, CAPE, Ro 09-1978/000, Xeloda, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis
National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
01/07
 
NCT00025337: Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

Completed
3
880
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU
National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
04/07
 
NCT00087802 / 2004-005250-31: Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

Completed
3
383
US
gemcitabine/Eloxatin (GEMOX), carboplatin/paclitaxel (CP)
Sanofi
Carcinoma, Non-Small-Cell Lung
05/07
 
NCT00052962: Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis

Completed
3
30
US
Cytoreductive surgery, Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)
National Cancer Institute (NCI)
Gastrointestinal Neoplasm
09/08
09/08
NCT00012389: Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

Completed
3
US, Canada, Europe, RoW
irinotecan hydrochloride, oxaliplatin
Sanofi
Colorectal Cancer
 
10/08
GEMOXIAL, NCT00470340 / 2006-005456-32: Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients

Terminated
3
263
Europe
Oxaliplatin, gemcitabine, cisplatin, lipiodol
Assistance Publique - Hôpitaux de Paris
Liver Neoplasms, Liver Cirrhosis, Carcinoma, Hepatocellular, Recurrence, Neoplasm Recurrence, Local
11/08
11/08
NCT00208546: Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Checkmark Data-ASCO
May 2011 - May 2011: Data-ASCO
Checkmark Biomarker data
Apr 2011 - Apr 2011: Biomarker data
Checkmark Biomarker data
More
Completed
3
750
Europe
21Capecitabine + bevacizumab + oxaliplatin, 1Capecitabine + oxaliplatin + bevacizumab + cetuximab
Dutch Colorectal Cancer Group, Koningin Wilhelmina Fonds, Sanofi, Roche Pharma AG, Immunicon
Colorectal Cancer
07/09
12/09
NCT00305188 / 2005-002570-30: Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Completed
3
879
US, Canada, Europe, RoW
Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, 5-FU, Leucovorin, LV
Sanofi
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
10/09
10/09
NCT00471965: Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

Completed
3
371
RoW
Oxaliplatin + 5-Fluorouracil/Leucovorin, Doxorubicin
Sanofi
Carcinoma, Hepatocellular
03/10
03/10
AVANT, NCT00112918: Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

Checkmark Data-ASCO
May 2011 - May 2011: Data-ASCO
Completed
3
3451
US
Bevacizumab, Capecitabine, Xeloda®, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin
Hoffmann-La Roche, National Cancer Institute (NCI)
Colorectal Cancer
06/10
06/12
NCT01524094: Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis

Completed
3
49
Europe
Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin), Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)
Uppsala University
Colorectal Peritoneal Carcinomatosis
12/10
01/12
NCT01149122: Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma

Checkmark AACR 2015
Mar 2015 - Mar 2015: AACR 2015
Checkmark P3 data
Dec 2011 - Dec 2011: P3 data
Completed
3
266
RoW
Gemcitabine/Oxaliplatin, Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)
Samsung Medical Center
Unresectable, Metastatic Biliary Tract Carcinoma
01/12
06/12
ITACA-S2, NCT01989858 / 2010-021052-25: (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)

Terminated
3
1180
Europe
peri-operative cht, post-operative CHT, peri-operative cht + post-operative cht-rtx, post-operative cht + post-operative cht-rtx
Mario Negri Institute for Pharmacological Research
Gastric Adenocarcinoma
12/13
12/13
NCT02445209: Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma

Completed
3
56
Europe
EOX, mDCF
Jagiellonian University
HER2 Negative Gastric Cancer
02/14
02/14
SECOX, NCT01245582: Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients

Withdrawn
3
0
RoW
oxaliplatin (SR96669), capecitabine, sorafenib
Sanofi
Hepatic Neoplasm Malignant
02/14
08/15
NCT01748851: XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)

Terminated
3
42
RoW
XELOX, Xeloda, FOLFOX, 5-FU
Dong-A University Hospital
Gastric Carcinoma Stage IV
09/14
09/14
NCT00769405 / 2006-006175-20: Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Completed
3
264
Europe
fluorouracil, leucovorin calcium, oxaliplatin, hyperthermia treatment
UNICANCER
Colorectal Cancer, Primary Peritoneal Cavity Cancer
12/15
 
NCT02149771: Combination Treatment for Advanced Liver Cancer

Withdrawn
3
0
RoW
chemoembolization, endovascular stents implantation, iodine-125 seed strand implantation
Shanghai Zhongshan Hospital, Shanghai Municipal Science and Technology Commission
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
05/16
09/16
NCT00068692: Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer

Completed
3
225
US
Radiotherapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, external radiation, Fluorouracil, Efudex, 5-FU, 5-Fluorouracil, Adrucil, Leucovorin Calcium, Leucovorin, Wellcovorin, citrovorun factor, folinic acid, LV, LCV, 5-formyl tetrahydrofolate, Oxaliplatin, 1-OHP, Dacplat, Eloxatin, Eloxatine, Trans-l-diaminocyclohexane oxalatoplatinum, Cis-[oxalato (trans-I-1 ,2-diaminocyclohexane) platinum(lI)], cis -[(1R,2R)-1,2-cyclohexanediamine- N,N'] [oxalate(2-)- 0,0'] platinum, Irinotecan, Camptosar, CPT-11, Camptothecin-11
National Cancer Institute (NCI)
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7, Stage IIB Rectal Cancer AJCC v7, Stage IIC Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
11/16
11/16
NCT01824459: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

Completed
3
576
RoW
S-1, Oxaliplatin, Cisplatin
Sun Yat-sen University, Taiho Pharmaceutical Co., Ltd.
Gastric Cancer
12/18
12/18
NCT03179579: Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer

Unknown status
3
88
RoW
HIPEC with neoadjuvant chemotherapy, CRS with HIPEC and adjuvant cheomtherapy, Systemic chemotherapy, CRS with systemic chemotherpay
Shu-Zhong Cui, Tianjin Medical University Cancer Institute and Hospital, Chinese PLA General Hospital, Harbin Medical University, Southern Medical University, China, Guangdong Provincial People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine
Gastric Cancer, Peritoneal Carcinomatosis
08/21
08/22
FAST, NCT00735241: FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

Withdrawn
2/3
0
US
SIR-Spheres microspheres, FOLFOX6 cycles 1-3, Eloxatin, Folinic acid, 5-FU, FOLFOX6 cycles 4 onwards, Bevacizumab cycles 3 onwards, Avastin
Sirtex Medical
Colorectal Carcinoma, Liver Metastases
03/09
03/09
NCT00861094: Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

Completed
2/3
266
Europe
cisplatin, 5-FU, 5-Fluorouracil, oxaliplatin, radiation therapy, Folinic Acid
UNICANCER
Esophageal Cancer
09/11
12/12
NCT02220088: The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Terminated
2/3
79
RoW
TAI of FOLFOX, Transcatheter arterial infusion of oxaliplatin , fluorouracil, and leucovorin, Sorafenib
Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital
Hepatocellular Carcinoma
07/18
07/18

Download Options